In this multicenter, real-world study, we evaluated the clinical, pathological, and immune-nutritional factors associated with pCR in patients with stage II–III HER2-positive breast cancer treated with neoadjuvant anti-HER2-based therapy. Here, ERBB2 is linked to breast cancer.